"sample_name"	"unique_patient_ID"	"alt_sample_name"	"sample_type"	"primarysite"	"summarygrade"	"G"	"summarystage"	"T"	"N"	"M"	"Dstage"	"age_at_initial_pathologic_diagnosis"	"days_to_tumor_recurrence"	"recurrence_status"	"days_to_death"	"vital_status"	"family_history"	"msi"	"location"	"summarylocation"	"gender"	"kras"	"braf"	"line1"	"tumor_size"	"mutation_apc"	"lymphnodesremoved"	"lymphnodesinvaded"	"stageall"	"ethnicity"	"dfs_status"	"days_to_recurrence_or_death"	"disease_specific_mortality"	"batch"	"drug_name"	"drug_treatment"	"drug_response"	"preop_drug_treatment"	"preop_drug_name"	"fu"	"bevacizumab"	"irinotecan"	"cetuximab"	"capecitabine"	"dexamethasone"	"gcsf"	"fudr"	"folfiri"	"folfox"	"leucovorin"	"mitomycin"	"platin"	"panitumumab"	"pegfilgrastim"	"raltitrexed"	"ancillary"	"chemotherapy"	"moltherapy"	"uncurated_author_metadata"
"GSM283127"	NA	"CRC_celecoxib_M4858"	"tumor"	NA	"low"	"2"	"late"	"3"	"1"	"1"	NA	NA	NA	NA	NA	NA	NA	NA	"sigmoid"	"l"	"m"	NA	NA	NA	NA	NA	NA	NA	"4"	NA	NA	NA	NA	"2003-08-19"	NA	NA	NA	"y"	"celecoxib"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_celecoxib_M4858///geo_accession: GSM283127///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: Celecoxib_#4858///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Male///characteristics_ch1.1: AJCC Stage: IV///characteristics_ch1.2: Pathological T: 3///characteristics_ch1.3: Pathological N: 1///characteristics_ch1.4: Pathological M: 1///characteristics_ch1.5: Grade: moderate///characteristics_ch1.6: Tumor Site: Sigmoid///characteristics_ch1.7: Drug Treatment: YES///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4858///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283127/GSM283127_5392.CEL.gz///data_row_count: 12625"
"GSM283128"	NA	"CRC_nodrug_F4860"	"tumor"	NA	"high"	"3"	"late"	"3"	"1"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"caecum"	"r"	"f"	NA	NA	NA	NA	NA	NA	NA	"3"	NA	NA	NA	NA	"2003-08-19"	NA	NA	NA	"n"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_nodrug_F4860///geo_accession: GSM283128///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: No_drug_#4860///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: AJCC Stage: III///characteristics_ch1.2: Pathological T: 3///characteristics_ch1.3: Pathological N: 1///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: poor///characteristics_ch1.6: Tumor Site: Cecum///characteristics_ch1.7: Drug Treatment: NO///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4860///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283128/GSM283128_5394.CEL.gz///data_row_count: 12625"
"GSM283129"	NA	"CRC_celecoxib_M4867"	"tumor"	NA	"low"	"2"	"early"	"3"	"0"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"caecum"	"r"	"m"	NA	NA	NA	NA	NA	NA	NA	"2"	NA	NA	NA	NA	"2003-08-19"	NA	NA	NA	"y"	"celecoxib"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_celecoxib_M4867///geo_accession: GSM283129///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: Celecoxib_#4867///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Male///characteristics_ch1.1: AJCC Stage: II///characteristics_ch1.2: Pathological T: 3///characteristics_ch1.3: Pathological N: 0///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: moderate///characteristics_ch1.6: Tumor Site: Cecum///characteristics_ch1.7: Drug Treatment: YES///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4867///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283129/GSM283129_5401.CEL.gz///data_row_count: 12625"
"GSM283130"	NA	"CRC_nodrug_M4868"	"tumor"	NA	"low"	"2"	"late"	"3"	"1"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"rectosigmoid"	"l"	"m"	NA	NA	NA	NA	NA	NA	NA	"3"	NA	NA	NA	NA	"2003-08-19"	NA	NA	NA	"n"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_nodrug_M4868///geo_accession: GSM283130///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: No_drug_#4868///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Male///characteristics_ch1.1: AJCC Stage: III///characteristics_ch1.2: Pathological T: 3///characteristics_ch1.3: Pathological N: 1///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: moderate///characteristics_ch1.6: Tumor Site: Rectosigmoid///characteristics_ch1.7: Drug Treatment: NO///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4868///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283130/GSM283130_5402.CEL.gz///data_row_count: 12625"
"GSM283131"	NA	"CRC_nodrug_M4870"	"tumor"	NA	"high"	"3"	"late"	"4"	"0"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"hepaticflexure"	"r"	"m"	NA	NA	NA	NA	NA	NA	NA	"2"	NA	NA	NA	NA	"2003-08-19"	NA	NA	NA	"n"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_nodrug_M4870///geo_accession: GSM283131///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: No_drug_#4870///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Male///characteristics_ch1.1: AJCC Stage: II///characteristics_ch1.2: Pathological T: 4///characteristics_ch1.3: Pathological N: 0///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: poor///characteristics_ch1.6: Tumor Site: Hepatic Flexure///characteristics_ch1.7: Drug Treatment: NO///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4870///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283131/GSM283131_5403.CEL.gz///data_row_count: 12625"
"GSM283132"	NA	"CRC_celecoxib_F4871"	"tumor"	NA	"low"	"1"	"early"	"2"	"0"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"sigmoid"	"l"	"f"	NA	NA	NA	NA	NA	NA	NA	"1"	NA	NA	NA	NA	"2003-08-19"	NA	NA	NA	"y"	"celecoxib"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_celecoxib_F4871///geo_accession: GSM283132///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: Celecoxib_#4871///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: AJCC Stage: I///characteristics_ch1.2: Pathological T: 2///characteristics_ch1.3: Pathological N: 0///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: well///characteristics_ch1.6: Tumor Site: Sigmoid///characteristics_ch1.7: Drug Treatment: YES///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4871///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283132/GSM283132_5404.CEL.gz///data_row_count: 12625"
"GSM283133"	NA	"CRC_nodrug_F4872"	"tumor"	NA	"low"	"2"	"early"	"2"	"0"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"caecum"	"r"	"f"	NA	NA	NA	NA	NA	NA	NA	"1"	NA	NA	NA	NA	"2003-08-19"	NA	NA	NA	"n"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_nodrug_F4872///geo_accession: GSM283133///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: No_drug_#4872///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: AJCC Stage: I///characteristics_ch1.2: Pathological T: 2///characteristics_ch1.3: Pathological N: 0///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: moderate///characteristics_ch1.6: Tumor Site: Cecum///characteristics_ch1.7: Drug Treatment: NO///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4872///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283133/GSM283133_5405.CEL.gz///data_row_count: 12625"
"GSM283134"	NA	"CRC_celecoxib_F4873"	"tumor"	NA	"low"	"2"	"late"	"3"	"1"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"ascending"	"r"	"f"	NA	NA	NA	NA	NA	NA	NA	"3"	NA	NA	NA	NA	"2003-08-19"	NA	NA	NA	"y"	"celecoxib"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_celecoxib_F4873///geo_accession: GSM283134///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: Celecoxib_#4873///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: AJCC Stage: III///characteristics_ch1.2: Pathological T: 3///characteristics_ch1.3: Pathological N: 1///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: moderate///characteristics_ch1.6: Tumor Site: Ascending///characteristics_ch1.7: Drug Treatment: YES///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4873///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283134/GSM283134_5406.CEL.gz///data_row_count: 12625"
"GSM283135"	NA	"CRC_celecoxib_F4874"	"tumor"	NA	"low"	"1"	"late"	"3"	"0"	"1"	NA	NA	NA	NA	NA	NA	NA	NA	"hepaticflexure"	"r"	"f"	NA	NA	NA	NA	NA	NA	NA	"4"	NA	NA	NA	NA	"2003-08-19"	NA	NA	NA	"y"	"celecoxib"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_celecoxib_F4874///geo_accession: GSM283135///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: Celecoxib_#4874///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: AJCC Stage: IV///characteristics_ch1.2: Pathological T: 3///characteristics_ch1.3: Pathological N: 0///characteristics_ch1.4: Pathological M: 1///characteristics_ch1.5: Grade: well///characteristics_ch1.6: Tumor Site: Hepatic Flexure///characteristics_ch1.7: Drug Treatment: YES///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4874///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283135/GSM283135_5407.CEL.gz///data_row_count: 12625"
"GSM283136"	NA	"CRC_celecoxib_M4875"	"tumor"	NA	"high"	"3"	"early"	"3"	"0"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"descending"	"l"	"m"	NA	NA	NA	NA	NA	NA	NA	"2"	NA	NA	NA	NA	"2003-08-19"	NA	NA	NA	"y"	"celecoxib"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_celecoxib_M4875///geo_accession: GSM283136///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: Celecoxib_#4875///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Male///characteristics_ch1.1: AJCC Stage: II///characteristics_ch1.2: Pathological T: 3///characteristics_ch1.3: Pathological N: 0///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: moderate to poor///characteristics_ch1.6: Tumor Site: Descending///characteristics_ch1.7: Drug Treatment: YES///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4875///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283136/GSM283136_5408.CEL.gz///data_row_count: 12625"
"GSM283137"	NA	"CRC_nodrug_M4876"	"tumor"	NA	"low"	"2"	"early"	"2"	"0"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"caecum"	"r"	"m"	NA	NA	NA	NA	NA	NA	NA	"1"	NA	NA	NA	NA	"2003-08-19"	NA	NA	NA	"n"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_nodrug_M4876///geo_accession: GSM283137///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: No_drug_#4876///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Male///characteristics_ch1.1: AJCC Stage: I///characteristics_ch1.2: Pathological T: 2///characteristics_ch1.3: Pathological N: 0///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: moderate///characteristics_ch1.6: Tumor Site: Cecum///characteristics_ch1.7: Drug Treatment: NO///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4876///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283137/GSM283137_5409.CEL.gz///data_row_count: 12625"
"GSM283138"	NA	"CRC_celecoxib_M4877"	"tumor"	NA	"high"	"3"	"early"	"3"	"0"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"caecum"	"r"	"m"	NA	NA	NA	NA	NA	NA	NA	"2"	NA	NA	NA	NA	"2003-08-19"	NA	NA	NA	"y"	"celecoxib"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_celecoxib_M4877///geo_accession: GSM283138///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: Celecoxib_#4877///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Male///characteristics_ch1.1: AJCC Stage: II///characteristics_ch1.2: Pathological T: 3///characteristics_ch1.3: Pathological N: 0///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: poor///characteristics_ch1.6: Tumor Site: Cecum///characteristics_ch1.7: Drug Treatment: YES///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4877///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283138/GSM283138_5410.CEL.gz///data_row_count: 12625"
"GSM283139"	NA	"CRC_nodrug_F4879"	"tumor"	NA	"low"	"1"	"early"	"3"	"0"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"ascending"	"r"	"f"	NA	NA	NA	NA	NA	NA	NA	"2"	NA	NA	NA	NA	"2003-08-19"	NA	NA	NA	"n"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_nodrug_F4879///geo_accession: GSM283139///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: No_drug_#4879///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: AJCC Stage: II///characteristics_ch1.2: Pathological T: 3///characteristics_ch1.3: Pathological N: 0///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: well///characteristics_ch1.6: Tumor Site: Ascending///characteristics_ch1.7: Drug Treatment: NO///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4879///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283139/GSM283139_5411.CEL.gz///data_row_count: 12625"
"GSM283140"	NA	"CRC_nodrug_F4881"	"tumor"	NA	"low"	"2"	"late"	"3"	"2"	"1"	NA	NA	NA	NA	NA	NA	NA	NA	"sigmoid"	"l"	"f"	NA	NA	NA	NA	NA	NA	NA	"4"	NA	NA	NA	NA	"2003-08-19"	NA	NA	NA	"n"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_nodrug_F4881///geo_accession: GSM283140///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: No_drug_#4881///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: AJCC Stage: IV///characteristics_ch1.2: Pathological T: 3///characteristics_ch1.3: Pathological N: 2///characteristics_ch1.4: Pathological M: 1///characteristics_ch1.5: Grade: moderate///characteristics_ch1.6: Tumor Site: Sigmoid///characteristics_ch1.7: Drug Treatment: NO///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4881///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283140/GSM283140_5413.CEL.gz///data_row_count: 12625"
"GSM283141"	NA	"CRC_nodrug_F4882"	"tumor"	NA	"low"	"2"	"early"	"3"	"0"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"sigmoid"	"l"	"f"	NA	NA	NA	NA	NA	NA	NA	"2"	NA	NA	NA	NA	"2003-08-19"	NA	NA	NA	"n"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_nodrug_F4882///geo_accession: GSM283141///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: No_drug_#4882///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: AJCC Stage: II///characteristics_ch1.2: Pathological T: 3///characteristics_ch1.3: Pathological N: 0///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: moderate///characteristics_ch1.6: Tumor Site: Sigmoid///characteristics_ch1.7: Drug Treatment: NO///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4882///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283141/GSM283141_5414.CEL.gz///data_row_count: 12625"
"GSM283142"	NA	"CRC_celecoxib_F4859"	"tumor"	NA	"low"	"2"	"early"	"1"	"0"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"ascending"	"r"	"f"	NA	NA	NA	NA	NA	NA	NA	"1"	NA	NA	NA	NA	"2003-08-28"	NA	NA	NA	"y"	"celecoxib"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_celecoxib_F4859///geo_accession: GSM283142///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: Celecoxib_#4859///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: AJCC Stage: I///characteristics_ch1.2: Pathological T: 1///characteristics_ch1.3: Pathological N: 0///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: moderate///characteristics_ch1.6: Tumor Site: Ascending///characteristics_ch1.7: Drug Treatment: YES///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4859///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283142/GSM283142_5440.CEL.gz///data_row_count: 12625"
"GSM283143"	NA	"CRC_nodrug_M4865"	"tumor"	NA	"low"	"2"	"late"	"4"	"1"	"1"	NA	NA	NA	NA	NA	NA	NA	NA	"ascending"	"r"	"m"	NA	NA	NA	NA	NA	NA	NA	"4"	NA	NA	NA	NA	"2003-08-28"	NA	NA	NA	"n"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_nodrug_M4865///geo_accession: GSM283143///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: No_drug_#4865///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Male///characteristics_ch1.1: AJCC Stage: IV///characteristics_ch1.2: Pathological T: 4///characteristics_ch1.3: Pathological N: 1///characteristics_ch1.4: Pathological M: 1///characteristics_ch1.5: Grade: moderate///characteristics_ch1.6: Tumor Site: Ascending///characteristics_ch1.7: Drug Treatment: NO///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4865///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283143/GSM283143_5441.CEL.gz///data_row_count: 12625"
"GSM283144"	NA	"CRC_nodrug_F4863"	"tumor"	NA	"low"	"2"	"early"	"3"	"0"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"sigmoid"	"l"	"f"	NA	NA	NA	NA	NA	NA	NA	"2"	NA	NA	NA	NA	"2003-08-28"	NA	NA	NA	"n"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_nodrug_F4863///geo_accession: GSM283144///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: No_drug_#4863///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: AJCC Stage: II///characteristics_ch1.2: Pathological T: 3///characteristics_ch1.3: Pathological N: 0///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: moderate///characteristics_ch1.6: Tumor Site: Sigmoid///characteristics_ch1.7: Drug Treatment: NO///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4863///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283144/GSM283144_5442.CEL.gz///data_row_count: 12625"
"GSM283145"	NA	"CRC_celecoxib_M4861"	"tumor"	NA	"low"	"2"	"late"	"3"	"1"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"caecum"	"r"	"m"	NA	NA	NA	NA	NA	NA	NA	"3"	NA	NA	NA	NA	"2003-08-28"	NA	NA	NA	"y"	"celecoxib"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_celecoxib_M4861///geo_accession: GSM283145///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: Celecoxib_#4861///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Male///characteristics_ch1.1: AJCC Stage: III///characteristics_ch1.2: Pathological T: 3///characteristics_ch1.3: Pathological N: 1///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: moderate///characteristics_ch1.6: Tumor Site: Cecum///characteristics_ch1.7: Drug Treatment: YES///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4861///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283145/GSM283145_5443.CEL.gz///data_row_count: 12625"
"GSM283146"	NA	"CRC_nodrug_F4862"	"tumor"	NA	"low"	"2"	"early"	"3"	"0"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"rectosigmoid"	"l"	"f"	NA	NA	NA	NA	NA	NA	NA	"2"	NA	NA	NA	NA	"2003-08-28"	NA	NA	NA	"n"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_nodrug_F4862///geo_accession: GSM283146///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: No_drug_#4862///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: AJCC Stage: II///characteristics_ch1.2: Pathological T: 3///characteristics_ch1.3: Pathological N: 0///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: moderate///characteristics_ch1.6: Tumor Site: Rectosigmoid///characteristics_ch1.7: Drug Treatment: NO///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4862///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283146/GSM283146_5444.CEL.gz///data_row_count: 12625"
"GSM283147"	NA	"CRC_celecoxib_F4880"	"tumor"	NA	"low"	"2"	"late"	"4"	"0"	"1"	NA	NA	NA	NA	NA	NA	NA	NA	"sigmoid"	"l"	"f"	NA	NA	NA	NA	NA	NA	NA	"4"	NA	NA	NA	NA	"2003-08-28"	NA	NA	NA	"y"	"celecoxib"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_celecoxib_F4880///geo_accession: GSM283147///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: Celecoxib_#4880///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: AJCC Stage: IV///characteristics_ch1.2: Pathological T: 4///characteristics_ch1.3: Pathological N: 0///characteristics_ch1.4: Pathological M: 1///characteristics_ch1.5: Grade: moderate///characteristics_ch1.6: Tumor Site: Sigmoid///characteristics_ch1.7: Drug Treatment: YES///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4880///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283147/GSM283147_5445.CEL.gz///data_row_count: 12625"
"GSM283148"	NA	"CRC_celecoxib_M4866"	"tumor"	NA	"low"	"2"	"late"	"3"	"1"	"1"	NA	NA	NA	NA	NA	NA	NA	NA	"ascending"	"r"	"m"	NA	NA	NA	NA	NA	NA	NA	"4"	NA	NA	NA	NA	"2003-08-28"	NA	NA	NA	"y"	"celecoxib"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_celecoxib_M4866///geo_accession: GSM283148///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: Celecoxib_#4866///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Male///characteristics_ch1.1: AJCC Stage: IV///characteristics_ch1.2: Pathological T: 3///characteristics_ch1.3: Pathological N: 1///characteristics_ch1.4: Pathological M: 1///characteristics_ch1.5: Grade: moderate///characteristics_ch1.6: Tumor Site: Ascending///characteristics_ch1.7: Drug Treatment: YES///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4866///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283148/GSM283148_5446.CEL.gz///data_row_count: 12625"
"GSM283149"	NA	"CRC_nodrug_F4864"	"tumor"	NA	"low"	"2"	"early"	"3"	"0"	"0"	NA	NA	NA	NA	NA	NA	NA	NA	"caecum"	"r"	"f"	NA	NA	NA	NA	NA	NA	NA	"2"	NA	NA	NA	NA	"2003-08-28"	NA	NA	NA	"n"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"title: CRC_nodrug_F4864///geo_accession: GSM283149///status: Public on Aug 21 2008///submission_date: Apr 22 2008///last_update_date: Mar 16 2009///type: RNA///channel_count: 1///source_name_ch1: No_drug_#4864///organism_ch1: Homo sapiens///characteristics_ch1: Gender: Female///characteristics_ch1.1: AJCC Stage: II///characteristics_ch1.2: Pathological T: 3///characteristics_ch1.3: Pathological N: 0///characteristics_ch1.4: Pathological M: 0///characteristics_ch1.5: Grade: moderate///characteristics_ch1.6: Tumor Site: Cecum///characteristics_ch1.7: Drug Treatment: NO///biomaterial_provider_ch1: Siteman Cancer Center Multiplex Gene Expression Core (St. Louis, MO)///treatment_protocol_ch1: Patients undergoing surgical resection of histologically proven primary colorectal adenocarcinomas were consented for participation in the study.  The patients enrolled in this study were randomized to receive either 400 mg celecoxib two times per day (n=11) or no COX-2 inhibitor (n=12) for 7 days prior to surgical resection.///molecule_ch1: total RNA///extract_protocol_ch1: Total RNA was isolated from surgically resected, histologically confirmed colorectal primary adenocarcinomas using a TRIzol RNA isolation kit (Invitrogen, Carlsbad, CA) according to the manufacturers recommended protocol at the Siteman Cancer Center Tissue Procurement Core (St. Louis, MO).///label_ch1: biotin///label_protocol_ch1: standard Affymetrix protocol///taxid_ch1: 9606///hyb_protocol: standard Affymetrix protocol///scan_protocol: standard Affymetrix protocol///description: 4864///data_processing: Affymetrix .cel files were imported into GeneSpring GX 7.3 using GC-RMA File Preprocessor.  Data was normalized by (1) setting all expression measurements <0.01 to 0.01, (2) a per chip normalization to the 50th percentile, and (3) a per gene normalization to the median value across all chips.///platform_id: GPL8300///contact_name: James,Todd,Auman///contact_email: jtauman@email.unc.edu///contact_phone: (919) 966-9942///contact_department: Institute for Pharmacogenomics and Individualized Therapy///contact_institute: University of North Carolina at Chapel Hill///contact_address: 3304 Kerr Hall, Campus Box 7360///contact_city: Chapel Hill///contact_state: NC///contact_zip.postal_code: 27599-7360///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/supplementary/samples/GSM283nnn/GSM283149/GSM283149_5447.CEL.gz///data_row_count: 12625"
